CREATIVE REALITIES, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CREATIVE REALITIES, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $18.44M | Mar 22, 2022 |
| FY2021 | Dec 31, 2020 | $17.46M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $31.60M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $22.48M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $17.70M | Mar 28, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $17.70M | Mar 26, 2018 |
| FY2017 | Dec 31, 2016 | $13.67M | Mar 26, 2018 |
| FY2016 | Dec 31, 2015 | $11.47M | Mar 28, 2017 |
| FY2015 | Dec 31, 2014 | $13.42M | Apr 4, 2016 |
| FY2013 | Dec 31, 2013 | $1.24M | Mar 11, 2014 |
| FY2013 | Sep 30, 2013 | $1.53M | Mar 11, 2014 |
| FY2013 | Jun 30, 2013 | $2.63M | Mar 11, 2014 |
| FY2013 | Mar 31, 2013 | $1.41M | Mar 11, 2014 |
| FY2012 | Dec 31, 2012 | $1.61M | Mar 1, 2013 |
| FY2013 | Sep 30, 2012 | $1.77M | Mar 11, 2014 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.71M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $24.01M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $22.18M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $17.74M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $8.36M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $8.12M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $13.74M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $10.22M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $7.39M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $6.86M | Mar 26, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.28M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($3.51M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($2.94M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $1.88M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $232.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($16.84M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $1.04M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($10.62M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($6.95M) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | ($4.70M) | Mar 26, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.87M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $938.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $1.35M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($2.48M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($2.55M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($16.08M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($110.0K) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($4.48M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($6.10M) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | ($4.56M) | Mar 26, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $1.57M | Mar 21, 2024 |
| FY2023 | Dec 31, 2022 | $1.25M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $550.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $1.08M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $1.41M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $1.26M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $991.0K | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $893.0K | Mar 26, 2018 |
| FY2016 | Dec 31, 2015 | $804.0K | Mar 28, 2017 |
| FY2015 | Dec 31, 2014 | $492.0K | Apr 4, 2016 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.75M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $3.38M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $5.17M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($708.0K) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $471.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($3.53M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($970.0K) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($1.56M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $655.0K | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | ($4.11M) | Mar 26, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $306.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $11.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $306.0K | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $149.0K | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $19.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $92.0K | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $897.0K | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $308.0K | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $569.0K | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $292.0K | Mar 26, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $151.04M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $65.21M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $70.78M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $66.02M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $22.88M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $20.62M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $33.98M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $37.73M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $26.05M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $24.42M | Mar 26, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $101.85M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $39.75M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $41.95M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $40.44M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $14.15M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $16.28M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $15.65M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $20.91M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $19.77M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $16.01M | Mar 26, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.50M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $25.46M | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | $28.83M | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | $25.58M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $8.73M | Mar 21, 2024 |
| FY2022 | Dec 31, 2020 | $4.34M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $18.51M | Mar 22, 2022 |
| FY2020 | Dec 31, 2018 | $16.82M | Mar 10, 2021 |
| FY2019 | Dec 31, 2017 | $4.35M | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | $4.48M | Mar 28, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.27M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $26.45M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $26.45M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $26.45M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $7.53M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $7.53M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $18.17M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $18.90M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $14.99M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $14.99M | Mar 26, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($65.13M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($56.85M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($53.35M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($50.41M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($52.25M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($52.49M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($35.64M) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($36.85M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($26.23M) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | ($19.28M) | Mar 26, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.56M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $1.04M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $2.91M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $1.63M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $2.88M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $1.83M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $2.53M | Mar 10, 2021 |
| FY2020 | Dec 31, 2018 | $2.72M | Mar 10, 2021 |
| FY2019 | Dec 31, 2017 | $1.00M | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | $1.35M | Mar 28, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $43.95M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $13.04M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $13.52M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $17.57M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $6.88M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $8.26M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $3.76M | Mar 10, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | (2) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | (2) | Mar 28, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Mar 14, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | (2) | Mar 13, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10.52M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 10.45M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 10.41M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | 7.27M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 4.00M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 10.92M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | 9.78M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | 9,725 | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | 2,753 | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | 66,649 | Mar 26, 2018 |